156 related articles for article (PubMed ID: 22651685)
21. Optimization of the assembly efficiency for lidamycin chromophore bound to its apoprotein: a case study using orthogonal array.
Zhong GS; Guo XF; Zhang SH; Zhen YS
Biomed Environ Sci; 2011 Dec; 24(6):602-7. PubMed ID: 22365395
[TBL] [Abstract][Full Text] [Related]
22. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
[TBL] [Abstract][Full Text] [Related]
23. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
[TBL] [Abstract][Full Text] [Related]
24. MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine.
Qin Y; Liu XJ; Li L; Liu XJ; Li Y; Gao RJ; Shao RG; Zhen YS
Oncol Rep; 2014 Jul; 32(1):121-30. PubMed ID: 24807584
[TBL] [Abstract][Full Text] [Related]
25. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
26. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
[TBL] [Abstract][Full Text] [Related]
27. A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.
He S; Zhao C; Tao H; Sheng W; Gao R; Liu X; Zhen Y
Drug Deliv; 2022 Dec; 29(1):1243-1256. PubMed ID: 35416106
[TBL] [Abstract][Full Text] [Related]
28. Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma.
Liu WJ; Zhu KL; Xu J; Wang JL; Zhu H
Lab Invest; 2018 Dec; 98(12):1538-1548. PubMed ID: 30206309
[TBL] [Abstract][Full Text] [Related]
29. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule.
Huang YH; Shang BY; Zhen YS
World J Gastroenterol; 2005 Jul; 11(26):3980-4. PubMed ID: 15996019
[TBL] [Abstract][Full Text] [Related]
30. Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy.
Zhong GS; Wu MN; Guo XF; Xu ZS; Zhang SH; Zhen YS
Oncol Lett; 2013 Apr; 5(4):1183-1188. PubMed ID: 23599760
[TBL] [Abstract][Full Text] [Related]
31. An arginine-rich cell penetrating peptide contained anti-gelatinase scFv-LDM fusion protein shows potent antitumor efficacy in pancreatic cancer.
Zhong G; Xu Z; Yang R; Zhang S; Li L; Wu M; Liu H; Zhen Y
J Cancer; 2018; 9(4):674-682. PubMed ID: 29556325
[TBL] [Abstract][Full Text] [Related]
32. Construction of a genetically engineered chimeric apoprotein consisting of sequences derived from lidamycin and neocarzinostatin.
Jiang W; Shang B; Li L; Zhang S; Zhen Y
Anticancer Drugs; 2016 Jan; 27(1):24-8. PubMed ID: 26457548
[TBL] [Abstract][Full Text] [Related]
33. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy.
Xu J; Du Y; Liu XJ; Zhu BY; Zhang SH; Li L; Li Y; Wang XF; Shan CK; Wang RQ; Zhen YS
Pharmacol Res; 2017 Dec; 126():66-76. PubMed ID: 28392461
[TBL] [Abstract][Full Text] [Related]
34. [Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
Shang BY; Shang Y; Zhen YS; Chen SZ
Yao Xue Xue Bao; 2011 Nov; 46(11):1321-5. PubMed ID: 22260022
[TBL] [Abstract][Full Text] [Related]
35. A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers.
Zhou DD; Zhai XT; Zhang LW; Xie ZH; Wang Y; Zhen YS; Gao RJ; Miao QF
NPJ Precis Oncol; 2024 Apr; 8(1):94. PubMed ID: 38654141
[TBL] [Abstract][Full Text] [Related]
36. The Recombinant and Reconstituted Novel Albumin-Lidamycin Conjugate Shows Lasting Tumor Imaging and Intensively Enhanced Therapeutic Efficacy.
Li L; Hu L; Zhao CY; Zhang SH; Wang R; Li Y; Shao RG; Zhen YS
Bioconjug Chem; 2018 Sep; 29(9):3104-3112. PubMed ID: 30105903
[TBL] [Abstract][Full Text] [Related]
37. EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis.
Liu WJ; Liu XJ; Xu J; Li L; Li Y; Zhang SH; Wang JL; Miao QF; Zhen YS
Acta Pharmacol Sin; 2018 Nov; 39(11):1777-1786. PubMed ID: 30013033
[TBL] [Abstract][Full Text] [Related]
38. Binding capability of the enediyne-associated apoprotein to human tumors and constitution of a ligand oligopeptide-integrated protein.
Cai L; Chen H; Miao Q; Wu S; Shang Y; Zhen Y
J Biotechnol; 2009 Oct; 144(2):142-50. PubMed ID: 19737585
[TBL] [Abstract][Full Text] [Related]
39. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.
Xu J; Liu XJ; Li L; Zhang SH; Li Y; Gao RJ; Zhen YS
Oncotarget; 2015 Sep; 6(28):26322-34. PubMed ID: 26314845
[TBL] [Abstract][Full Text] [Related]
40. [Binding capability of lidamycin apoprotein to human breast cancer detected by tissue microarrays].
Cai L; Gao RJ; Guo XZ; Li Y; Zhen YS
Yao Xue Xue Bao; 2010 May; 45(5):582-8. PubMed ID: 20931759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
